Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2019

View Archived Issues

New antibody against F glycoprotein prevents membrane fusion and viral entry in NiV, HeV infections

Novel dietary-induced mouse model of NASH with severe fibrosis

Celldex reports results from ongoing phase I study of CDX-1140

Enrollment ongoing in phase III study of TV P2-VP8 vaccine

Pfizer initiates phase III study of PF-06741086

Phase IIb ATLAS study of etokimab fails to meet the primary endpoint

Update given for the phase III JAVELIN gastric 100 trial

UMC Utrecht Holding discloses thombolytic fusion proteins

IL-38 protein compositions described by Reyoung Suzhou Biology Science & Technology

FORMA Therapeutics discovers histone deacetylase 11 inhibitors

Medshine Discovery patents Rho kinase inhibitors

Roche and Genentech identify new RIP-1 inhibitors

Simpler recipe makes better cocktail for iPSCs

Exosomes help brain metastases along

Novel AVV-based vector therapy for the treatment of AD

New DREADD tools for noninvasive manipulation and visualization of neuronal circuits in animals

Zelluna Immunotherapy presents novel compound, ZI-H04, as cancer immunotherapeutic

Glecaprevir/pibrentasvir investigated in young children with chronic HCV infection

Now, Sleeping Beauty is the fairest of them all

NKTR-358 safe and well tolerated in first-in-human study

SUNFISH study of risdiplam in type 2 and 3 SMA meets primary endpoint

FDA approves Reblozyl for anemia in beta thalassemia requiring regular RBC transfusions

First-in-human comparison of LY-2775240 and apremilast in healthy volunteers

New phase IIa study investigates use of MTPS-9579A in asthma

Lyvgen initiates first-in-human study of LVGN-6051 in advanced or metastatic malignancy

Roche announces discontinuation of RG-6206 development in DMD

Oncogene-linked prodrug strategy for selective KEAP1 mutant NSCLC cytotoxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.